Hologic, Inc.
250 Campus Drive
Marlborough
Massachusetts
01752
United States
Tel: 781-999-7300
Fax: 781-280-0669
Website: http://www.hologic.com/
Email: support@hologic.com
644 articles about Hologic, Inc.
-
Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography
4/11/2024
Bayer and Hologic, Inc. (Nasdaq: HOLX) today announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM).
-
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024
4/2/2024
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2024 on Thursday, May 2, after the market closes.
-
Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
3/5/2024
Hologic, Inc. and its subsidiary, Biotheranostics, Inc., announced newly published study results revealing that use of the Breast Cancer Index® test led to physicians changing their long-term anti-estrogen treatment recommendations for 40% of patients with early-stage hormone receptor-positive breast cancer.
-
Hologic to Unveil Groundbreaking AI Research at ECR 2024
2/27/2024
Hologic, Inc. (Nasdaq: HOLX) continues to deliver on its commitment to advancing women’s health by unveiling new research in artificial intelligence (AI) and offering innovative educational opportunities at the annual European Congress of Radiology (ECR) in Vienna, Austria from February 28 to March 2.
-
Hologic to Webcast Presentations at Upcoming Investor Conferences - February 26, 2024
2/26/2024
Hologic, Inc. announced that the Company will present at the following upcoming investor conferences: Raymond James' 45th Annual Institutional Investors Conference on Monday, March 4 at 8:40 a.m. Eastern Time.
-
Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System
2/1/2024
Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm has received clearance from the U.S. Food and Drug Administration (FDA), making it the first and only FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.
-
Hologic Announces Financial Results for First Quarter of Fiscal 2024
2/1/2024
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 30, 2023.
-
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2024
1/7/2024
Hologic, Inc. announced preliminary revenue results for its first fiscal quarter ended December 30, 2023.
-
Hologic to Announce Financial Results for the First Quarter of Fiscal 2024 on Thursday, February 1, 2024
1/4/2024
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes.
-
Hologic to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. Pacific Time.
-
Hologic to Showcase Developments in Next-Generation AI Solutions at RSNA 2023
11/24/2023
Hologic, Inc. (Nasdaq: HOLX) will showcase several recent developments in next-generation AI solutions at the 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 26 to 30.
-
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2023
11/9/2023
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 30, 2023.
-
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2023 on Thursday, November 9, 2023
10/5/2023
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2023 on Thursday, November 9, after the market closes.
-
Hologic to Webcast Presentations at Upcoming September 2023 Investor Conferences
8/30/2023
Hologic, Inc. announced that the Company will present at the following upcoming investor conferences.
-
Hologic Announces Financial Results for Third Quarter of Fiscal 2023
7/31/2023
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended July 1, 2023.
-
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2023 on Monday, July 31, 2023
7/5/2023
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2023 on Monday, July 31, after the market closes.
-
Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
5/19/2023
Hologic Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay.
-
Hologic to Webcast Presentation at the BofA Securities 2023 Healthcare Conference
5/2/2023
Hologic, Inc. announced that the Company will present at the BofA Securities 2023 Healthcare Conference in Las Vegas, NV on Tuesday, May 9 at 2:20 p.m. Pacific Time.
-
Hologic Announces Financial Results for Second Quarter of Fiscal 2023
5/1/2023
Hologic, Inc. announced the Company’s financial results for the fiscal second quarter ended April 1, 2023.
-
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2023 on Monday, May 1, 2023
4/3/2023
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2023 on Monday, May 1, after the market closes.